1020656-47-6

Upstream product

• 108-30-5 succinic acid anhydride 
• 2740-83-2 3-(TRIFLUOROMETHYL)BENZYLAMINE 

Downstream Products

• 1020655-99-5 4-oxo-4-(1-(thiophen-2-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2-yl)-N-(3-(trifluoromethyl)benzyl)butanamide 
• 1229513-87-4 4-oxo-4-(1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-N-(3-(trifluoromethyl)benzyl)butyric acid amide 
• 1229513-91-0 4-oxo-4-(1-thien-2-yl-3,4-dihydro-1H-isoquinolin-2-yl)-N-(3-(trifluoromethyl)benzyl)butyric acid amide 
• 1229514-07-1 4-(4-methyl-1-phenyl-3,4-dihydro-1H-isoquinolin-2-yl)-4-oxo-N-[[3-(trifluoromethyl)phenyl]methyl]butyric acid amide 
• 1224392-50-0 4-oxo-4-(5-phenyl-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-N-(3-(trifluoromethyl)benzyl)butanamide 
• 1224391-72-3 4-(4-(3-fluorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-4-oxo-N-(3-(trifluoromethyl)benzyl)butanamide 
• 1224391-84-7 4-oxo-4-(7-phenyl-4,5-dihydrothieno[2,3-c]pyridin-6(7H)-yl)-N-(3-(trifluoromethyl)benzyl)butanamide 
• 1224391-70-1 4-oxo-4-(4-phenyl-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-N-(3-(trifluoromethyl)benzyl)butanamide 

Relevant academic research and scientific papers

Substituted 4,5,6,7-tetrahydrothienopyridines as KCNQ2/3 Modulators

Substituted tetrahydrothienopyridines corresponding to formula (1) in which A1 through A3 and R1 through R12 have defined meanings, pharmaceutical compositions comprising such compounds, a process for preparing such compounds and the use of such compounds in treatment or inhibition of conditions mediated by the KCNQ 2/3 K+ channel, e.g., pain.

SUBSTITUTED 4-(1,2,3,4-TETRAHYDROISOQUINOLIN-2-YL)-4-OXORUTYRIC ACID AMIDE AS KCNQ2/3 MODULATORS

The invention relates to substituted tetrahydroisoquinolinyl-4-oxobutyric acid amides, methods for the preparation thereof, medicinal products containing these compounds and the use of these compounds for the preparation of medicinal products

Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in the Treatment and/or Inhibition of Pain

Substituted tetrahydropyrrolopyrazine compounds corresponding to the formula I: processes for their preparation, pharmaceutical compositions comprising these compounds and the use of these compounds for the treatment and/or inhibition of pain and other disorders or disease states at least partly mediated by KCNQ2/3 K+ channels.